Hereditary bleeding disorders

Factor II (prothrombin) deficiency

Last author update: 1 August 2010
Last staff update: 16 September 2020

Copyright: 2002-2024,, Inc.

PubMed Search: Factor II (prothrombin) deficiency [title]

Kendall Crookston, M.D., Ph.D.
Julie Kim Harrington, M.D.
Page views in 2024 to date: 45
Cite this page: Crookston K, Rosenbaum LS, Gober-Wilcox J. Factor II (prothrombin) deficiency. website. Accessed May 19th, 2024.
Definition / general
  • Congenital deficiency of prothrombin (factor II) that results in reduced prothrombin activity and normal or reduced prothrombin antigen levels
  • Prothrombin (factor II) is a vitamin-K dependent cofactor which is activated by factor Xa to form thrombin, which then converts fibrinogen to fibrin
  • Hypoprothrombinemia (type I deficiency) is a decrease in the overall synthesis of prothrombin and is characterized by reduced prothrombin activity and antigen levels
  • Dysprothrombinemia (type II deficiency) is the synthesis of dysfunctional prothrombin molecules and is characterized by reduced activity and normal antigen levels
  • Rare; fewer than 100 cases have been reported
  • Prevalence rate of approximately 1:2,000,000 in the general population
  • Mucocutaneous and soft tissue bleeding (see below)
  • 40 different mutations in the prothrombin gene have been identified, the majority of which are missense mutations (~80%). However, insertion or deletion mutations (~10%) and nonsense mutations (~4%) have also been identified.
  • The gene is transmitted in an autosomal recessive pattern with homozygous, heterozygous or compound heterozygous genotypes
  • Homozygous individuals have functional prothrombin levels of 2 - 25%
  • Heterozygous patients have prothrombin levels of 40 - 60%
  • Biologic half life is 48 - 120 hours
Diagrams / tables

Images hosted on other servers:

Coagulation cascade

Clinical features
  • Complete deficiency is incompatible with life
  • Severe hemorrhage typically occurs when levels are < 5%
  • Need levels of 10 - 40% for surgical hemostasis
  • Patients have lifelong history or family history of bleeding; varies from asymptomatic to minor bleeding to severe bleeding (depending on the mutation)
  • Also easy bruising, postoperative bleeding, epistaxis, menorrhagia, miscarriage, postpartum hemorrhage, hemarthroses and intracranial bleeding (if severe deficiency)
  • Prolonged PT and PTT that correct with mixing study (1:1 mixture of patient and normal pooled plasma)
  • Type I (true deficiency) patients will have both activity and antigen levels < 10%
  • Type II patients will have normal antigen levels and low activity
  • Recombinant factor VIIa, alternatively 10 - 20 ml fresh frozen plasma/kg, then 3 ml/kg every 12 - 24 hours as necessary
  • Plasma infusion for recurrent bleeding episodes every 3 - 5 weeks
  • Prothrombin complex concentrates may be used for serious bleeding
Differential diagnosis
Back to top
Image 01 Image 02